WHO raises Ebola risk in DRC to 'very high' amid ongoing conflict
Compare the reporting
Significant discrepancy in confirmed case count.
Open the listed sources to review each publisher’s original wording.
Story essentials
World Health Organization (WHO), UN
Democratic Republic of the Congo (DRC), Uganda
This page is produced by collecting and structuring multiple public reports. Sections based only on reporting or testimony affect the displayed assessment, and the page is updated when new information is identified.
About this article
COMPAMIR Editorial Team
The COMPAMIR editorial team brings together public reporting and links to the original coverage. We update the page as new information emerges.
Read our editorial policyRead next
Prioritized by shared people, places, and events.
Oxford University begins clinical trials for Bundibugyo Ebola vaccine
Oxford University has administered the first dose of a vaccine targeting the Bundibugyo strain of Ebola. The outbreak in DRC and Uganda has caused over 1,270 deaths and nearly 3,000 infections since May. The vaccine candidate was developed in eight weeks using technology similar to the AstraZeneca Covid-19 vaccine. WHO warns that the actual number of cases could be twice as high due to conflict-related access issues.
Related book
The Coming Plague: Newly Emerging Diseases in a World Out of Balance
Author: Laurie Garrett
This classic work provides a comprehensive look at how emerging infectious diseases like Ebola interact with global environmental changes and human behavior, offering essential context for understanding why outbreaks in regions like the DRC remain a persistent global threat.
As an Amazon Associate, COMPAMIR earns from qualifying purchases.